PIPERACILLIN ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H27N5O7S
Molecular Weight	517.555
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N3CCN(CC)C(=O)C3=O)C4=CC=CC=C4)C(O)=O

InChI

InChIKey=IVBHGBMCVLDMKU-GXNBUGAJSA-N

InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H27N5O7S
Molecular Weight	517.555
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68010878

Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in combination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Penicillin-binding protein 1A 45 Target ID: Q8DR59 Gene ID: 934791.0 Gene Symbol: pbpA Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Binding Agent 1059		940.0 nM [IC50]
Penicillin-binding protein 2B 10 Target ID: P0A3M6 Gene ID: 933948.0 Gene Symbol: penA Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Binding Agent 1059		51.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Intra-abdominal infections 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8360	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 7.5116157E11
Skin and skin structure infections 80 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8360	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 7.5116157E11
Female pelvic infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8360	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 7.5116157E11
Community-acquired pneumonia 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8360	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 7.5116157E11
Nosocomial pneumonia 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050684s084s086,050750s034s035lbl.pdf	Curative	Approved 8360	ZOSYN Approved Use ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: - Intra-abdominal infections; - Skin and skin structure infections; - Female pelvic infections; - Community-acquired pneumonia; - Nosocomial pneumonia. Launch Date 7.5116157E11

C_max

Value	Dose	Co-administered	Analyte	Population
150 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
344.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23590897/	4.5 g single, intravenous dose: 4.5 g route of administration: Intravenous experiment type: SINGLE co-administered:		PIPERACILLIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Other AEs: Thrombophlebitis, Injection site pain... Other AEs: Thrombophlebitis (4%) Injection site pain (2%) Injection site erythema (2%) Injection site induration (2%) Diarrhea (2%) Loose stools (2%) Rash (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Other AEs: Thrombophlebitis, Injection site pain... Other AEs: Thrombophlebitis (4%) Injection site pain (2%) Injection site erythema (2%) Injection site induration (2%) Diarrhea (2%) Loose stools (2%) Rash (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf

AEs

AE	Significance	Dose	Population
Rash	1%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Diarrhea	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site erythema	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site induration	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site pain	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Loose stools	2%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Thrombophlebitis	4%	2 g 4 times / day multiple, intramuscular Dose: 2 g, 4 times / day Route: intramuscular Route: multiple Dose: 2 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Rash	1%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Diarrhea	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site erythema	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site induration	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Injection site pain	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Loose stools	2%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
Thrombophlebitis	4%	4 g 4 times / day multiple, intravenous Dose: 4 g, 4 times / day Route: intravenous Route: multiple Dose: 4 g, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	unhealthy Health Status: unhealthy Condition: serious infections caused by susceptible strains Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579 inducer 768	inhibitor 1752 inducer 383

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A5 73 CYP2C8 901 OAT1 595 OAT3 636	OAT1 320 OAT3 333	CYP3A5 76 P-gp 257

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1803	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP2C9 1803	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A4 1909	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A5 130	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
CYP3A5 130	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	no
P-gp 1626	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/11850258/	no
CYP2C8 955	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/26763401/	weak [IC50 1140 uM]
OAT1 599	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/32104494/	yes
OAT3 638	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/32104494/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT3 333	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/29277663/	yes [Km 172 uM]
OAT1 320	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/29277663/	yes [Km 37 uM]

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01410	http://www.3bsc.com/index/pro_info.php?id=21622
3B Scientific (Wuhan) Corp	3B2-1697	http://www.3bsc.com/index/pro_info.php?id=56231
AHH Chemical co.,ltd	MT-58012	http://www.ahhchemical.com/product/MT-58012.html
AHH Chemical co.,ltd	MT-58917	http://www.ahhchemical.com/product/MT-58917.html
AK Scientific, Inc. (AKSCI)	J10085	http://www.aksci.com/item_detail.php?cat=J10085
Achemtek	0102-022374	http://www.achemtek.com/61477-96-1
Angene	AGN-PC-0T0LDB	http://www.angenechemical.com/productshow/AGN-PC-0T0LDB.html
Aurora Fine Chemicals LLC	A13.110.313	http://online.aurorafinechemicals.com/info?ID=A13.110.313
Aurum Pharmatech LLC	KM0517	http://www.Aurumpharmatech.com/Product/ProductDetails/KM0517
AvaChem Scientific	4535	http://www.avachem.com/productSearch.asp?4535
BLD Pharm	BD239259	http://www.bldpharm.com/products/61477-96-1.html
BioSynth	W-105153	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/W-105153.html
ChemMol	49424430	http://www.chemmol.com/chemmol/49424430.html
ChemMol	99119834	http://www.chemmol.com/chemmol/99119834.html
Chemspace	CSSB00016990198	https://chem-space.com/CSSB00016990198
Clearsynth	CS-O-14488	https://www.clearsynth.com/en/CSO14488.html
Glentham Life Sciences	GA9881	http://www.glentham.com/products/product/GA9881/
Hairui	HR134010	http://www.hairuichem.com/en/product/61477-96-1.html
LGC Standards	DRE-C16218900	https://www.lgcstandards.com/US/en/p/DRE-C16218900
LGC Standards	LGCFOR0295.00	https://www.lgcstandards.com/US/en/p/LGCFOR0295.00
LGC Standards	MM0295.00	https://www.lgcstandards.com/US/en/p/MM0295.00
Lab Network	LN00199061	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00199061
Matrix Scientific	97252	https://www.matrixscientific.com/097252.html
MuseChem	R011373	https://www.musechem.com/product/R011373.html
OChem	6047	http://www.ocheminc.com/index.php?act=psearch&pid=477P961
Parchem	44935	https://www.parchem.com/chemical-supplier-distributor/Pipracil-044935.aspx
Smolecule	S589373	https://www.smolecule.com/products/s589373
THE BioTek	bt-505814	https://www.thebiotek.com/product/others/bt-505814
Yuhao Chemical	RT10348	http://www.chemyuhao.com/61477-96-1.html
abcr GmbH	AB479648	http://www.abcr.com/shop/en/AB479648
iChemical	EBD29493	http://www.ichemical.com/chemicals/cas-61477-96-1

PubMed

Title	Date	PubMed
[Use of the Etest method for antimicrobial susceptibility testing of obligate anaerobes].	2001	11757426
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.	2001	11735679
Infections caused by Flavimonas oryzihabitans.	2001 Apr	11780462
Chronic granulomatous disease: a case report.	2001 Apr	11393130
The immunomodulatory effects of gentamicin, imipenem, piperacillin and amphotericin B on LAK effector function in vitro.	2001 Apr	11335146
[Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin].	2001 Apr	11305007
Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.	2001 Apr-Jun	11432485
An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.	2001 Aug	11589485
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp].	2001 Aug	11558128
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.	2001 Aug	11545486
[Interventional ERCP in patients with cholestasis. Degree of biliary bacterial colonization and antibiotic resistance].	2001 Dec	11753782
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.	2001 Dec	11737119
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.	2001 Dec	11733473
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].	2001 Feb	11338681
[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].	2001 Jan 10	11798851
[Surveillance of bacterial resistance in Shanghai].	2001 Jan 10	11798844
A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.	2001 Jul	11699402
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).	2001 Jul	11502382
Faecal concentrations of piperacillin and tazobactam in elderly patients.	2001 Jul	11418534
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?	2001 Jul-Aug	11399859
[Analysis of the risk factors and drug resistance of lower respiratory tract infection by Flavobacteria].	2001 Jun	11802986
Surveillance of bacterial resistance among isolates in Shanghai in 1999.	2001 Jun	11455503
Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin.	2001 Jun	11422785
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.	2001 Jun	11389111
Ultraviolet recall-like phenomenon occurring after piperacillin, tobramycin, and ciprofloxacin therapy.	2001 Jun	11369921
Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.	2001 Mar	11318813
Seroprevalence and antibiotic sensitivity of serotypes of Salmonella enterica in Greek pig herds.	2001 Mar 31	11327648
Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates.	2001 May	11337223
Ureidopenicillins and risk of Clostridium difficile infection.	2001 May	11328794
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.	2001 May 15	11320454
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs.	2001 May-Jun	11395191
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!	2001 Nov	11750171
Hand infections in patients with diabetes mellitus.	2001 Nov	11727802
Stability of piperacillin and ticarcillin in AutoDose infusion system bags.	2001 Nov	11724082
In vitro antimicrobial susceptibility of Aerococcus urinae to 14 antibiotics, and time-kill curves for penicillin, gentamicin and vancomycin.	2001 Nov	11679554
CAPD-associated peritonitis caused by Alcaligenes xylosoxidans sp. xylosoxidans.	2001 Nov-Dec	11799270
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.	2001 Oct 15	11565068
Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.	2001 Sep	11714046
Isolation and culture of airway epithelial cells from chronically infected human lungs.	2001 Sep	11669281
[Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].	2001 Sep	11642016
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001 Sep	11642015
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.	2001 Sep	11549103
Effect of mono-dose intraperitoneal cecropins in experimental septic shock.	2001 Sep	11546961
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.	2001 Sep	11533004
Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999.	2002 Feb	11897073
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.	2002 Feb	11815589
Antibiotic-induced recurring interstitial nephritis.	2002 Jan	11793135
Surveillance for antimicrobial resistance in Croatia.	2002 Jan	11749742
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).	2002 Mar	11864948

Patents

Sample Use Guides

In Vivo Use Guide

The usual total daily dose of ZOSYN® for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). The usual duration of ZOSYN® treatment is from 7 to 10 days. ZOSYN® should be administered by intravenous infusion over 30 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC values for piperacillin/tazobactam were: 1-4 ug/ml (Escherichia coli ATCC 25922), 0.5-2 ug/ml (Escherichia coli ATCC 35218), 1-8 ug/ml (Pseudomonas aeruginosa ATCC 27853), 0.06-0.5 ug/ml (Haemophilus influenzae ATCC 49247), 0.25-2 ug/ml (Staphylococcus aureus ATCC 29213), 0.12-0.5 ug/ml (Bacteroides fragilis ATCC 25285), 4-16 ug/ml (Bacteroides thetaiotaomicron ATCC 29741).

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:15:41 UTC 2023` Edited by `admin` on `Wed Jul 05 23:15:41 UTC 2023`
Record UNII	9I628532GX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIPERACILLIN ANHYDROUS

Common Name

English

Piperacillin [WHO-DD]

Common Name

English

PIPERACILLIN [MART.]

Common Name

English

PERACIN

Brand Name

English

PIPERACILLIN, ANHYDROUS

Common Name

English

PIPERACILLIN [JAN]

Common Name

English

piperacillin [INN]

Common Name

English

PIPERACILLIN [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175497